Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1409]

ASCO 2023: Addition of olaparib and durvalumab prolonged progression-free survival in patients with advanced ovarian cancer

ASCO 2023: Addition of olaparib and durvalumab prolonged progression-free survival in patients with advanced...

Initiative will test new drug combinations guided by tumour biology

Initiative will test new drug combinations guided by tumour biology

NCCN joins collaboration to improve standards in cancer care for vietnam

NCCN joins collaboration to improve standards in cancer care for vietnam

ASCO 2023: Adding pembrolizumab to chemotherapy improves survival in people with advanced cervical cancer

ASCO 2023: Adding pembrolizumab to chemotherapy improves survival in people with advanced cervical cancer 

ASCO 2023: Safety & efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid & CNS tumours

ASCO 2023: Safety & efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid & CNS tumours

NCCN global policy leader to co-chair GHC's non-communicable diseases roundtable

NCCN global policy leader to co-chair GHC's non-communicable diseases roundtable

Septic shock and metastases: finding the culprits

Septic shock and metastases: finding the culprits

Targeting uncontrolled inflammation may hold the key to treating therapy-resistant cancers

Targeting uncontrolled inflammation may hold the key to treating therapy-resistant cancers

Cervical cancer screening doubles when under-screened women are mailed testing kits

Cervical cancer screening doubles when under-screened women are mailed testing kits

Study highlights racial disparities in ovarian cancer risk for women

Study highlights racial disparities in ovarian cancer risk for women

More from ecancer